Defibrillation Safety Margin Testing in Patients With Congenital Heart Disease
- 1 September 2021
- journal article
- research article
- Published by Elsevier in JACC: Clinical Electrophysiology
- Vol. 7 (9) , 1145-1154
Abstract
No abstract availableKeywords
Funding Information
- Medtronic
- Abbott Laboratories
- Biotronik
- American College of Cardiology Foundation
- Bristol-Myers Squibb
- Biosense Webster
- Boston Scientific Corporation
- Janssen Pharmaceutica
- Pfizer
- ZOLL Medical Corporation
This publication has 18 references indexed in Scilit:
- Prevalence, predictors and complications with defibrillation threshold testing in pediatric patients: Results from the NCDRInternational Journal of Cardiology, 2020
- 2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testingHeart Rhythm, 2016
- Cardioverter defibrillator implantation without induction of ventricular fibrillation: a single-blind, non-inferiority, randomised controlled trial (SIMPLE)The Lancet, 2015
- Predictors of an Inadequate Defibrillation Safety Margin at ICD ImplantationJACC, 2014
- Prospective Evaluation of Defibrillation Threshold and Postshock Rhythm in Young ICD RecipientsPacing and Clinical Electrophysiology, 2012
- ICD Therapy in Children and Young Adults: Low Incidence of Inappropriate Shock DeliveryPacing and Clinical Electrophysiology, 2010
- Elevated defibrillation thresholds in patients undergoing biventricular defibrillator implantation: Incidence and predictorsHeart Rhythm, 2006
- Defibrillation Energy Requirements in an ICD Population Receiving Cardiac Resynchronization TherapyJournal of Cardiovascular Electrophysiology, 2006
- Utility of Routine Follow‐Up Defibrillator Threshold Testing in Congenital Heart Disease and Pediatric PopulationsJournal of Cardiovascular Electrophysiology, 2005
- High Defibrillation Thresholds in Transvenous Biphasic Implantable Defibrillators:Pacing and Clinical Electrophysiology, 2003